Nurix Therapeutics Reports Second Quarter Fiscal 2021 Financial Results and Provides a Corporate Update
Initiated Phase 1 trial of lead program NX-2127 in patients with relapsed or refractory B-cell malignancies On track to initiate…
Pharmaceuticals, Biotechnology and Life Sciences
Initiated Phase 1 trial of lead program NX-2127 in patients with relapsed or refractory B-cell malignancies On track to initiate…
Nordic Oil, a market leader in the European CBD industry, has launched its first ever crowdfunding campaignMUNICH, Germany, July 13,…
ImCheck Publishes Seminal Paper in Cell Reports Elucidating How Butyrophilins Activate Vγ9Vδ2 T cell Function Against Tumor Cells First published…
SpineX’s Proprietary SCONE™ Device Offers New Hope to Families of Children with CP SCONE Device SCONE LOS ANGELES, July 13,…
Infant Bacterial Therapeutics AB (publ) today announced that Marie-Louise Alamaa has been appointed Chief Financial Officer (CFO) effective from August…
Altadena, CA, July 13, 2021 (GLOBE NEWSWIRE) — Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) (“Lixte” or the “Company”) noted that…
Positive Results from Phase 2 Presbyopia (VEGA-1) and Phase 3 Reversal of Mydriasis (MIRA-2) Studies to be Presented at 2021…
WOBURN, Mass., July 13, 2021 (GLOBE NEWSWIRE) — Yield10 Bioscience, Inc. (Nasdaq: YTEN), an agricultural bioscience company, today announced it…
MELBOURNE, Australia, July 11, 2021 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) is pleased to announce…
—Multiple data presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2021 highlight durability of effect…